rs184660829 — DENND2C

DENND2C rs184660829 — A Rare Intronic Signal With a Large Diabetes Footprint

Most genetic risk variants for type 2 diabetes (T2D) are common, each nudging risk upward by a small amount. rs184660829 works differently: it is vanishingly rare — found in fewer than 1 in 2,500 people of European ancestry and essentially absent elsewhere — but carries one of the largest odds ratios for T2D yet identified in a genome-wide study. Carriers of the C allele face roughly 8 times the population risk of developing type 2 diabetes compared to the vast majority of people who carry two copies of the common T allele.

The Gene and Its Mechanism

DENND2C (DENN domain containing 2C¹¹ DENN domain containing 2C
a family of guanine nucleotide exchange factors (GEFs) that activate Rab GTPases) is a protein that controls vesicle trafficking — the cellular process by which membrane-bound packages of molecules are routed to their correct destinations. Rab GTPases are the molecular switches that direct this traffic, and DENND2C turns them on by catalyzing the exchange of GDP for GTP. Disruption of this switch-throwing activity has consequences for any tissue that depends on precise vesicle delivery, including the pancreatic beta cells that must release insulin granules on demand in response to rising blood glucose.

The rs184660829 variant sits 84 nucleotides upstream of a splice site in intron 11 of DENND2C (GRCh38: chr1:114,602,278, coding notation c.1668-84A>G on the minus strand). It is not in the protein-coding sequence and produces no amino acid change; instead, it may subtly alter splicing efficiency or local chromatin state in a tissue-specific way. The variant lies within a genomic region that, per islet epigenome maps used in the Mahajan 2018 fine-mapping study, shows regulatory chromatin marks in pancreatic islets — consistent with a gene-regulatory rather than structural mechanism.

The Evidence

Mahajan et al. (2018, Nature Genetics) fine-mapped T2D loci using high-density imputation in 898,130 European-descent individuals (71,124 cases, 824,006 controls) and integrated islet-specific epigenome data to prioritize functional signals.²² Mahajan et al. (2018, Nature Genetics) fine-mapped T2D loci using high-density imputation in 898,130 European-descent individuals (71,124 cases, 824,006 controls) and integrated islet-specific epigenome data to prioritize functional signals.
Mahajan A et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018 Nov;50(11):1505-1513. rs184660829-C emerged as one of the rare index variants (MAF <5%) with an estimated allelic odds ratio exceeding 2-fold — specifically OR=8.05 (95% CI 3.86–16.8, p=3×10⁻⁸), meeting genome-wide significance. The variant's risk allele frequency is approximately 2×10⁻⁴ globally, meaning the association was detected despite very few carriers, which underscores the strength of the biological signal.

Because the variant is intronic and its mechanism is not fully characterized, the evidence level is classified as moderate: the GWAS signal is genome-wide significant and the locus is biologically plausible, but functional validation in human islets and replication in non-European populations have not been published. The study was conducted exclusively in European-ancestry samples, and the C allele has not been observed at appreciable frequency in African, East Asian, South Asian, or Latino populations in gnomAD or ALFA population databases.

Practical Actions

Carriers of the C allele (TC genotype) should understand that their genetic background places them at substantially elevated T2D risk relative to the general population. The most evidence-backed strategies for individuals with high genetic T2D risk target fasting glucose monitoring and dietary carbohydrate quality — interventions with documented efficacy specifically in genetically at-risk individuals. Because the DENND2C locus likely affects beta cell vesicle function rather than insulin resistance in peripheral tissues, the primary vulnerability is in insulin secretion capacity, making monitoring of beta cell reserve (via fasting insulin and HOMA-B calculations) particularly informative.

Interactions

DENND2C rs184660829 is a recently discovered rare-variant signal and no published compound interactions with other T2D loci have been characterized. However, high-T2D-risk individuals carrying this allele who also carry common risk variants in TCF7L2 (rs7903146) or MTNR1B (rs10830963) may experience additive risk burden on a polygenic basis. These interactions are theoretical and have not been formally studied in the context of rs184660829.